Sign in
TLX Stock Price, Chart, Stats & News
Telix Pharmaceuticals Limited
Save
3.68B
Market cap
–
Current P/E
2000.00x
Forward P/E
TLX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 50.74% |
Operating margin | 2.11% |
Pretax margin | -0.66% |
Net margin | -0.88% |
Effective tax rate | -131.02% |
ROA | -0.61% |
ROE | -2.06% |
D/E | 1.26x |
Interest coverage ratio | 1.64x |
TLX valuation
P/E | – |
P/S | 3.73x |
P/B | 7.28x |
P/CF | -177.15x |
P/FCF | -59.82x |
P/OCF | -177.15x |
PEG | 2.25x |
EV multiple | 104.68x |
About
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer.
Similar securities
Based on sector and market capitalization
Report issue